Home » Zymogenetics Gets Bad News From FDA
Zymogenetics Gets Bad News From FDA
Officials at ZymoGenetics Inc. said that the Food and Drug Administration will take at least three more months to review the biotech’s rThrombin bleeding-control drug.
Puget Sound Business Journal
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May